Search

The effective development of a physician–leadership workforce enables trainees to keep pace with the dynamic and increasingly complex future of healthcare. [ABSTRACT FROM AUTHOR]

Background: venous thromboembolism (VTE) is a well-known complication in adults with acute lymphoblastic leukemia (ALL), especially in patients treatedwith asparaginase (ASNase)-including regiments. However, VTE risk in adult Philadelphia-positive ALL (Ph+ve ALL) patients treated with non-hyperCVADchemotherapy is unclear. In this study, we examinedVTE incidence in adult Ph+veALL patients treated with imatinib plus a pediatric-inspired asparaginase (ASNase)-free regimen modified from the Dana Farber Cancer Institute (DFCI) ALL protocol. Methods: a single centre retrospective review of Ph+ve ALL patients treated at Princess Margaret Cancer Center (PMCC) from 2008-2019 with imatinib plus modified DFCI protocol was conducted. Results: of the 123 patients included, 30 (24.3%) had at least 1 radiology confirmed VTE event from diagnosis to the end of maintenance therapy. 86.7% (26/30) of the VTE events occurred during active treatment. Of all VTE events, the majority (53.3%) were DVT and/or PE while another significant portion were catheter-related (40.0%). Major bleeding was observed in 1 patient on VTE treatment with low molecular weight heparin (LMWH). Conclusion: a high VTE incidence (24.3%) was observed in adults Ph+ve ALL patients treated with imatinib plus an ASNase-free modified DFCI pediatric ALL protocol, suggesting prophylactic anticoagulation should be considered for all adult Ph+ve ALL patients including those treated with ASNase-free regimens. [ABSTRACT FROM AUTHOR]

• Lower rates of cytokine release syndrome (CRS) are seen in haplo-hematopoietic stem cell transplantation using anti-thymocyte globulin (ATG) and post-transplant cyclophosphamide for graft-versus-host disease. • Severe CRS was not documented, but that needs to be assessed in a larger study. • ATG may reduce alloreactive T cells, resulting in a lower incidence of CRS. [ABSTRACT FROM AUTHOR]